• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种在重度血友病 A 患者中使用 ADVATE myPKFiT 剂量工具生成药代动力学特征的实用单诊次方案。

A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects.

机构信息

Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.

Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada.

出版信息

Thromb Haemost. 2021 Oct;121(10):1326-1336. doi: 10.1055/a-1376-0970. Epub 2021 Apr 14.

DOI:10.1055/a-1376-0970
PMID:33506480
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8494515/
Abstract

Standard pharmacokinetic (PK) assessments are demanding for persons with hemophilia A, requiring a 72-hour washout and 5 to 11 timed blood samples. A no-washout, single-clinic visit, sparse sampling population PK (PPK) protocol is an attractive alternative. Here, we compared PK parameters obtained with a traditional washout, 6-sampling time point PPK protocol with a no-washout, single-clinic visit, reverse 2-sampling time point PPK protocol in persons with severe hemophilia A (SHA) receiving ADVATE. A total of 39 inhibitor-negative males with SHA (factor VIII activity [FVIII:C] < 2%) were enrolled in a prospective sequential design PK study. Participants completed a washout, 6-sampling time point PPK protocol as well as a no-washout, reverse 2-sampling time point protocol, with samples taken during a single 3-hour clinic visit 24 hours post home infusion of FVIII and then 3 hours post infusion in clinic. FVIII:C levels were analyzed by one-stage and chromogenic assays; blood group and von Willebrand factor antigen (VWF:Ag) were determined; and PK parameters were analyzed using the ADVATE myPKFiT dosing tool. There was moderate to almost perfect agreement for the PK parameters obtained with the 2- and the 6- point PPK protocols using a one-stage FVIII:C assay and a substantial to almost perfect agreement using a chromogenic FVIII:C assay. Significant associations between specific PK parameters and blood group and VWF:Ag were observed. The no-washout, single-clinic visit, reverse 2-sampling time point PPK protocol can be used in the routine clinical setting since it demonstrates sufficient accuracy compared with the more demanding and less practical washout, 6-sampling time point PPK protocol in persons with SHA receiving ADVATE.

摘要

标准药代动力学(PK)评估对 A 型血友病患者要求较高,需要 72 小时洗脱期和 5 至 11 个时间点的采血。无洗脱、单次就诊、稀疏采样人群 PK(PPK)方案是一种有吸引力的替代方案。在这里,我们比较了接受 ADVATE 治疗的严重 A 型血友病(SHA)患者中,传统洗脱、6 个时间点 PPK 方案与无洗脱、单次就诊、反向 2 个时间点 PPK 方案获得的 PK 参数。共有 39 名抑制剂阴性男性 SHA(VIII 因子活性 [FVIII:C] < 2%)参与了一项前瞻性序贯设计 PK 研究。参与者完成了洗脱、6 个时间点 PPK 方案以及无洗脱、反向 2 个时间点方案,在家庭输注 FVIII 后 24 小时和在诊所输注后 3 小时的单次 3 小时诊所就诊期间采集样本。FVIII:C 水平通过一步法和显色法分析;血型和血管性血友病因子抗原(VWF:Ag)测定;并使用 ADVATE myPKFiT 剂量工具分析 PK 参数。使用一步法 FVIII:C 测定和显色 FVIII:C 测定,两种方案获得的 PK 参数具有中度至几乎完美的一致性。观察到特定 PK 参数与血型和 VWF:Ag 之间存在显著关联。与更具挑战性且不切实际的洗脱、6 个时间点 PPK 方案相比,无洗脱、单次就诊、反向 2 个时间点 PPK 方案在接受 ADVATE 治疗的 SHA 患者中具有足够的准确性,因此可以在常规临床环境中使用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a2f/8494515/319c87cedaa1/10-1055-a-1376-0970-i200529-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a2f/8494515/ca9c27d84828/10-1055-a-1376-0970-i200529-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a2f/8494515/131be2cb0da3/10-1055-a-1376-0970-i200529-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a2f/8494515/319c87cedaa1/10-1055-a-1376-0970-i200529-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a2f/8494515/ca9c27d84828/10-1055-a-1376-0970-i200529-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a2f/8494515/131be2cb0da3/10-1055-a-1376-0970-i200529-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a2f/8494515/319c87cedaa1/10-1055-a-1376-0970-i200529-3.jpg

相似文献

1
A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects.一种在重度血友病 A 患者中使用 ADVATE myPKFiT 剂量工具生成药代动力学特征的实用单诊次方案。
Thromb Haemost. 2021 Oct;121(10):1326-1336. doi: 10.1055/a-1376-0970. Epub 2021 Apr 14.
2
Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.儿童和成人血浆游离型和白蛋白结合型重组因子 VIII 的比较药代动力学:采血方案对观察到的与年龄相关差异的影响及其对剂量调整的意义。
J Thromb Haemost. 2010 Apr;8(4):730-6. doi: 10.1111/j.1538-7836.2010.03757.x.
3
Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.两种无血清重组凝血因子 VIII 制剂(N8 和 ADVATE®)的生物等效性——一项在严重甲型血友病患者中进行的开放性、序贯剂量药代动力学研究。
Haemophilia. 2011 Nov;17(6):854-9. doi: 10.1111/j.1365-2516.2011.02495.x. Epub 2011 Mar 28.
4
The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.B 结构域缺失重组凝血因子 VIII(turoctocog alfa,NovoEight®)在血友病 A 患者中的药代动力学。
J Thromb Haemost. 2015 Mar;13(3):370-9. doi: 10.1111/jth.12816. Epub 2015 Feb 13.
5
Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII.VIII 因子药代动力学指导剂量工具的交叉评估。
Thromb Haemost. 2018 Mar;118(3):514-525. doi: 10.1055/s-0038-1623531. Epub 2018 Mar 13.
6
Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.重组凝血因子 VIII Fc 融合蛋白:延长给药间隔可维持较低的出血率,并与血管性血友病因子水平相关。
J Thromb Haemost. 2014 Nov;12(11):1788-800. doi: 10.1111/jth.12723. Epub 2014 Oct 10.
7
Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens.VIII 因子在预防治疗重度 A 型血友病中的需求以维持目标血浆水平:药代动力学和治疗方案差异的影响。
J Thromb Haemost. 2010 Feb;8(2):269-75. doi: 10.1111/j.1538-7836.2009.03703.x. Epub 2009 Nov 23.
8
Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?两种延长半衰期 FVIII 浓缩物(Eloctate 和 Adynovate)在青少年血友病 A 患者中的比较药代动力学:是否存在差异?
J Thromb Haemost. 2019 Jul;17(7):1085-1096. doi: 10.1111/jth.14469. Epub 2019 Jun 2.
9
Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications.甲型血友病患者的围手术期治疗:O型血患者有出血并发症的风险。
J Thromb Haemost. 2016 Mar;14(3):468-78. doi: 10.1111/jth.13242. Epub 2016 Feb 19.
10
The "OPTI-CLOT" trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A.“OPTI-CLOT”试验。一项关于血友病A围手术期凝血因子浓缩物药代动力学指导给药的随机对照试验。
Thromb Haemost. 2015 Aug 31;114(3):639-44. doi: 10.1160/TH14-11-0925. Epub 2015 Jun 11.

引用本文的文献

1
Comparison Pharmacokinetic Dosing Tools in Hemophilia A Children.血友病A患儿中比较药代动力学给药工具
Indian J Hematol Blood Transfus. 2024 Jan;40(1):108-115. doi: 10.1007/s12288-023-01671-0. Epub 2023 May 22.
2
Clinical Predictors and Prediction Models for rFVIII-Fc Half Life in Real-World People with Severe Hemophilia A.重度A型血友病患者实际应用中重组凝血因子VIII-融合蛋白半衰期的临床预测指标及预测模型
J Clin Med. 2023 Mar 13;12(6):2207. doi: 10.3390/jcm12062207.
3
Correlation Analysis of DNA Methylation in the von Willebrand Factor Promoter Region and the Risk of Unexplained Recurrent Hemophilia: Systematic Review and Meta-Analysis.

本文引用的文献

1
Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS-Hemo project.WAPPS-Hemo 项目 FVIII 和 FIX 浓缩物的群体药代动力学模型的建立与评估。
Haemophilia. 2020 May;26(3):384-400. doi: 10.1111/hae.13977. Epub 2020 Apr 13.
2
Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review.利用药代动力学为血友病患者在凝血因子产品转换时定制预防方案:一项范围综述。
Res Pract Thromb Haemost. 2019 May 20;3(3):528-541. doi: 10.1002/rth2.12204. eCollection 2019 Jul.
3
Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates.
血管性血友病因子启动子区 DNA 甲基化与不明原因复发性血友病风险的相关性分析:系统评价和荟萃分析。
Contrast Media Mol Imaging. 2022 Jun 3;2022:3977289. doi: 10.1155/2022/3977289. eCollection 2022.
载脂蛋白 LDLR 功能多态性与凝血因子 VIII 浓缩物的药代动力学。
J Thromb Haemost. 2019 Aug;17(8):1288-1296. doi: 10.1111/jth.14473. Epub 2019 May 29.
4
Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?两种延长半衰期 FVIII 浓缩物(Eloctate 和 Adynovate)在青少年血友病 A 患者中的比较药代动力学:是否存在差异?
J Thromb Haemost. 2019 Jul;17(7):1085-1096. doi: 10.1111/jth.14469. Epub 2019 Jun 2.
5
Impact of Adopting Population Pharmacokinetics for Tailoring Prophylaxis in Haemophilia A Patients: A Historically Controlled Observational Study.采用群体药代动力学调整血友病 A 患者预防治疗的影响:一项历史性对照观察研究。
Thromb Haemost. 2019 Mar;119(3):368-376. doi: 10.1055/s-0039-1677700. Epub 2019 Jan 27.
6
Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing.基于基于人群药代动力学剂量调整的血友病 A 患者个体化预防治疗的临床结局。
Thromb Res. 2019 Jan;173:79-84. doi: 10.1016/j.thromres.2018.11.017. Epub 2018 Nov 16.
7
User's guide to correlation coefficients.相关系数用户指南。
Turk J Emerg Med. 2018 Aug 7;18(3):91-93. doi: 10.1016/j.tjem.2018.08.001. eCollection 2018 Sep.
8
Improvement in clinical outcomes and replacement factor VIII use in patients with haemophilia A after factor VIII pharmacokinetic-guided prophylaxis based on Bayesian models with myPKFiT.基于贝叶斯模型的 myPKFiT 的因子 VIII 药代动力学指导预防后,A型血友病患者的临床结局改善和因子 VIII 使用的替代。
Haemophilia. 2018 Sep;24(5):e338-e343. doi: 10.1111/hae.13540. Epub 2018 Jul 20.
9
Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?为血友病的个体化治疗奠定基础:药代动力学能发挥什么作用?
Blood Rev. 2018 Jul;32(4):265-271. doi: 10.1016/j.blre.2018.01.001. Epub 2018 Jan 31.
10
Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH.采用群体药代动力学方法评估和解读甲型或乙型血友病个体患者的药代动力学特征:国际血栓与止血学会科学和标准化委员会的通讯
J Thromb Haemost. 2017 Dec;15(12):2461-2465. doi: 10.1111/jth.13867. Epub 2017 Nov 9.